ODI PHARMA AB (6OD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ODI PHARMA AB (6OD) has a cash flow conversion efficiency ratio of 0.153x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€364.19K ≈ $425.78K USD) by net assets (€2.38 Million ≈ $2.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 6OD market cap overview for the company's overall valuation and market capitalisation.
ODI PHARMA AB - Cash Flow Conversion Efficiency Trend (2022–2026)
This chart illustrates how ODI PHARMA AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ODI PHARMA AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ODI PHARMA AB ranked by their cash flow conversion efficiency. Explore 6OD operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sriwahana
JK:SWAT
|
-0.044x |
|
NEWLOX GOLD VENTURES
F:NGO
|
-0.012x |
|
Ecofin Global Utilities and Infrastructure Trust plc
LSE:EGL
|
0.000x |
|
Geekco Technologies Corp
V:GKO
|
0.017x |
|
Science Group plc
LSE:SAG
|
0.102x |
|
Boustead Heavy Industries
KLSE:8133
|
-0.188x |
|
Falcon Gold Corp
V:FG
|
-0.004x |
|
AH-Vest Limited
JSE:AHL
|
-0.211x |
Annual Cash Flow Conversion Efficiency for ODI PHARMA AB (2022–2026)
The table below shows the annual cash flow conversion efficiency of ODI PHARMA AB from 2022 to 2026. View latest ODI PHARMA AB stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | €2.38 Million ≈ $2.78 Million |
€4.58 Million ≈ $5.35 Million |
1.926x | +124.75% |
| 2025-06-30 | €424.64K ≈ $496.45K |
€-3.31 Million ≈ $-3.86 Million |
-7.785x | -307.41% |
| 2024-06-30 | €2.00 Million ≈ $2.34 Million |
€-3.82 Million ≈ $-4.47 Million |
-1.911x | +3.68% |
| 2023-06-30 | €2.57 Million ≈ $3.01 Million |
€-5.10 Million ≈ $-5.97 Million |
-1.984x | -149.15% |
| 2022-06-30 | €9.26 Million ≈ $10.83 Million |
€-7.37 Million ≈ $-8.62 Million |
-0.796x | -- |
About ODI PHARMA AB
ODI Pharma AB (publ), a pharmaceutical company, engages in the production and distribution of pharmaceutical cannabis and cosmetics products in Europe. It offers dried flowers; and cosmetics products. ODI Pharma AB (publ) was founded in 2018 and is based in Stockholm, Sweden.